Blood test guided chemo after colon cancer surgery
Part of Cancer, Digestive system clinical trials.
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign an informed consent form and agree to follow the study plan
- You’re age 19 to 75, and you can be as active as allowed for your age
- Your colon cancer is adenocarcinoma, and it was stage II (high risk) or stage III
- After curative surgery (R0 resection), you finished FOLFOX (6 cycles) or CAPOX (4 cycles)
- Your ctDNA blood test done 3 to 6 weeks after surgery must be positive for MRD
- Your blood counts and organ function (liver, kidneys, bone marrow) must be within allowed limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks a blood test called circulating tumor DNA to help choose the best time and approach for chemotherapy after colon cancer surgery. It aims to reduce recurrence by identifying people who may benefit from treatment based on changes seen in the blood.
This trial tests whether checking for cancer DNA in your blood (ctDNA) can help doctors decide if you need extra chemotherapy after surgery for stage III colon cancer. It aims to personalize treatment and avoid unnecessary chemo.
This trial tests giving mFOLFIRINOX chemotherapy after curative surgery for people with high-risk stage III colon cancer. It aims to lower the chance that cancer comes back.
This trial checks whether a special blood test (ctDNA methylation) can help decide the best chemotherapy after surgery for people at higher risk of colon cancer coming back. It may help spare some patients unnecessary treatment while aiming to improve outcomes for those likely to relapse.
This trial tests whether a blood test that looks at cancer DNA can help decide whether you need “adjuvant” (extra) chemotherapy after colon cancer surgery. It may help some patients avoid unnecessary chemotherapy while still keeping the cancer from coming back.
This study uses a simple blood test to detect cancer DNA after surgery for early-stage colon cancer. The goal is to help doctors decide whether chemotherapy is truly needed based on the blood test results, rather than giving it to everyone.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.